Neonatal Research Institute
Clinical Trial: Premature Infants Resuscitated With Oxygen or Air
Oxygen is good for you — but how much is not known, especially in premature newborns.
Premature babies all have a risk of death, brain damage and eye damage, as well as poor development over the long term. This study will determine whether starting oxygen at different levels has any effect on an array of developmental milestones most commonly associated with premature babies.
Clinical trial: Premature Infants Resuscitated With Oxygen or Air (PRESOX)
Primary investigator: Dr. Neil Finer, a leader in neonatal resuscitation, is the overall principal investigator for the trial.
About this trial.
Our studies will test whether starting at 21 percent oxygen (the air we breathe) is different than giving extra oxygen — 60 percent — at birth for extremely premature babies.
Sharp Mary Birch Hospital for Women & Newborns will be the lead site for this study, which will be the largest oxygen trial even conducted. More than 1,250 babies will participate in this study, which will provide mass data for better patient outcomes. There will be more than 20 participating centers in the United States and Europe.
Our hypothesis is that starting at the air we breathe (21 percent) compared to giving extra oxygen (60 percent) will:
- Decrease death or eye damage
- Decrease death or long-term disabilities
To learn more about this study, visit ClinicalTrials.gov.
To learn more about the NICU at Sharp Mary Birch, visit Neonatal Intensive Care Unit. For more information about the NRI or to learn more about our clinical trials, send us an email or call 858-939-4112.